Literature DB >> 29776954

Role of Elevated PHIP Copy Number as a Prognostic and Progression Marker for Cutaneous Melanoma.

Vladimir Bezrookove1, Mehdi Nosrati1, James R Miller1, David De Semir1, Altaf A Dar1, Elham Vosoughi1, Edith Vaquero1, Antje Sucker2, Alexander J Lazar3, Jeffrey E Gershenwald3, Michael A Davies3, Dirk Schadendorf2, Mohammed Kashani-Sabet4.   

Abstract

Purpose: Previous studies have indicated an important role for pleckstrin homology domain-interacting protein (PHIP) as a marker and mediator of melanoma metastasis. Here we aimed to confirm the role of PHIP copy number in successive stages of melanoma progression.Experimental Design:PHIP copy number was examined using FISH in three independent cohorts by recording the percentage of cells harboring ≥3 copies of PHIP The impact of PHIP copy number on survival was assessed using Cox regression analysis. The enrichment of PHIP was assessed in various molecular melanoma subtypes. PHIP expression was analyzed in The Cancer Genome Atlas (TCGA) melanoma cohort.
Results: Elevated PHIP copy number was significantly predictive of reduced distant metastasis-free survival (DMFS) and disease-specific survival (DSS), and increased prevalence of ulceration in primary melanoma (cohort No. 1). By multivariate analysis, PHIP FISH scores were independently predictive of DMFS and DSS. PHIP copy number was enriched in metastatic melanomas harboring mutant NRAS or expressing PTEN protein (cohort No. 2). PHIP copy number was significantly elevated in metastatic melanomas when compared with matched primary tumors from the same patient (cohort No. 3). Several of these associations were replicated using TCGA cohort analysis.Conclusions: These results underscore the important role of PHIP copy-number elevation in melanoma progression, and identify molecular subtypes of melanoma in which PHIP is enriched. Finally, as elevated PHIP copy number appears to be selected for during the progression of primary to metastatic melanoma, these results confirm PHIP as a promising therapeutic target for melanoma. Clin Cancer Res; 24(17); 4119-25. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29776954      PMCID: PMC6125189          DOI: 10.1158/1078-0432.CCR-18-0791

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  14 in total

1.  Akt stimulates aerobic glycolysis in cancer cells.

Authors:  Rebecca L Elstrom; Daniel E Bauer; Monica Buzzai; Robyn Karnauskas; Marian H Harris; David R Plas; Hongming Zhuang; Ryan M Cinalli; Abass Alavi; Charles M Rudin; Craig B Thompson
Journal:  Cancer Res       Date:  2004-06-01       Impact factor: 12.701

2.  Cancer statistics, 2018.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-01-04       Impact factor: 508.702

3.  Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.

Authors:  C M Balch; S J Soong; J E Gershenwald; J F Thompson; D S Reintgen; N Cascinelli; M Urist; K M McMasters; M I Ross; J M Kirkwood; M B Atkins; J A Thompson; D G Coit; D Byrd; R Desmond; Y Zhang; P Y Liu; G H Lyman; A Morabito
Journal:  J Clin Oncol       Date:  2001-08-15       Impact factor: 44.544

4.  Genomic Classification of Cutaneous Melanoma.

Authors: 
Journal:  Cell       Date:  2015-06-18       Impact factor: 41.582

5.  Pleckstrin homology domain-interacting protein (PHIP) as a marker and mediator of melanoma metastasis.

Authors:  David De Semir; Mehdi Nosrati; Vladimir Bezrookove; Altaf A Dar; Scot Federman; Geraldine Bienvenu; Suraj Venna; Javier Rangel; Joan Climent; Tanja M Meyer Tamgüney; Suresh Thummala; Schuyler Tong; Stanley P L Leong; Chris Haqq; Paul Billings; James R Miller; Richard W Sagebiel; Robert Debs; Mohammed Kashani-Sabet
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-17       Impact factor: 11.205

6.  Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.

Authors:  Reinhard Dummer; Dirk Schadendorf; Paolo A Ascierto; Ana Arance; Caroline Dutriaux; Anna Maria Di Giacomo; Piotr Rutkowski; Michele Del Vecchio; Ralf Gutzmer; Mario Mandala; Luc Thomas; Lev Demidov; Claus Garbe; David Hogg; Gabriella Liszkay; Paola Queirolo; Ernesto Wasserman; James Ford; Marine Weill; L Andres Sirulnik; Valentine Jehl; Viviana Bozón; Georgina V Long; Keith Flaherty
Journal:  Lancet Oncol       Date:  2017-03-09       Impact factor: 41.316

7.  Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations.

Authors:  Amanda D Bucheit; Guo Chen; Alan Siroy; Michael Tetzlaff; Russell Broaddus; Denai Milton; Patricia Fox; Roland Bassett; Patrick Hwu; Jeffrey E Gershenwald; Alexander J Lazar; Michael A Davies
Journal:  Clin Cancer Res       Date:  2014-08-27       Impact factor: 12.531

8.  Akt and hypoxia-inducible factor-1 independently enhance tumor growth and angiogenesis.

Authors:  Andrew M Arsham; David R Plas; Craig B Thompson; M Celeste Simon
Journal:  Cancer Res       Date:  2004-05-15       Impact factor: 12.701

9.  Prognostic impact of PHIP copy number in melanoma: linkage to ulceration.

Authors:  Vladimir Bezrookove; David De Semir; Mehdi Nosrati; Schuyler Tong; Clayton Wu; Suresh Thummala; Altaf A Dar; Stanley P L Leong; James E Cleaver; Richard W Sagebiel; James R Miller; Mohammed Kashani-Sabet
Journal:  J Invest Dermatol       Date:  2013-09-04       Impact factor: 8.551

10.  A poised fragment library enables rapid synthetic expansion yielding the first reported inhibitors of PHIP(2), an atypical bromodomain.

Authors:  Oakley B Cox; Tobias Krojer; Patrick Collins; Octovia Monteiro; Romain Talon; Anthony Bradley; Oleg Fedorov; Jahangir Amin; Brian D Marsden; John Spencer; Frank von Delft; Paul E Brennan
Journal:  Chem Sci       Date:  2015-12-22       Impact factor: 9.825

View more
  8 in total

1.  PHIP drives glioblastoma motility and invasion by regulating the focal adhesion complex.

Authors:  David de Semir; Vladimir Bezrookove; Mehdi Nosrati; Kara R Scanlon; Eric Singer; Jonathon Judkins; Christopher Rieken; Clayton Wu; Julia Shen; Christina Schmudermayer; Altaf A Dar; James R Miller; Charles Cobbs; Garret Yount; Pierre-Yves Desprez; Robert J Debs; Nathan Salomonis; Sean McAllister; James E Cleaver; Liliana Soroceanu; Mohammed Kashani-Sabet
Journal:  Proc Natl Acad Sci U S A       Date:  2020-04-09       Impact factor: 11.205

2.  PHIPing along: Evolution of PHIP as a cancer biomarker and a target for therapy.

Authors:  Mohammed Kashani-Sabet; Vladimir Bezrookove; David de Semir
Journal:  Oncotarget       Date:  2018-11-16

3.  Identification of differentially expressed miRNAs in early-stage cervical cancer with lymph node metastasis across The Cancer Genome Atlas datasets.

Authors:  Qian Chen; Xiaoyun Zeng; Dongping Huang; Xiaoqiang Qiu
Journal:  Cancer Manag Res       Date:  2018-11-28       Impact factor: 3.989

4.  The RepID-CRL4 ubiquitin ligase complex regulates metaphase to anaphase transition via BUB3 degradation.

Authors:  Sang-Min Jang; Jenny F Nathans; Haiqing Fu; Christophe E Redon; Lisa M Jenkins; Bhushan L Thakur; Lőrinc S Pongor; Adrian M Baris; Jacob M Gross; Maura J OʹNeill; Fred E Indig; Steven D Cappell; Mirit I Aladjem
Journal:  Nat Commun       Date:  2020-01-07       Impact factor: 14.919

5.  circPHIP promotes oral squamous cell carcinoma progression by sponging miR-142-5p and regulating PHIP and ACTN4 expression.

Authors:  Wen Su; Yuehong Shen; Yufan Wang; Feng Wang; Xia Hong; Yuling Chen; Yuntao Lin; Hongyu Yang
Journal:  Mol Ther Nucleic Acids       Date:  2020-11-04       Impact factor: 8.886

6.  A trivalent nucleosome interaction by PHIP/BRWD2 is disrupted in neurodevelopmental disorders and cancer.

Authors:  Marc A J Morgan; Irina K Popova; Anup Vaidya; Jonathan M Burg; Matthew R Marunde; Emily J Rendleman; Zachary J Dumar; Rachel Watson; Matthew J Meiners; Sarah A Howard; Natalia Khalatyan; Robert M Vaughan; Scott B Rothbart; Michael-C Keogh; Ali Shilatifard
Journal:  Genes Dev       Date:  2021-11-24       Impact factor: 12.890

7.  Identification of multi-omics biomarkers and construction of the novel prognostic model for hepatocellular carcinoma.

Authors:  Xiao Liu; Chiying Xiao; Kunyan Yue; Min Chen; Hang Zhou; Xiaokai Yan
Journal:  Sci Rep       Date:  2022-07-15       Impact factor: 4.996

Review 8.  Ulcerated Cutaneous Melanoma: A Review of the Clinical, Histologic, and Molecular Features Associated with a Clinically Aggressive Histologic Phenotype.

Authors:  Zoe Barricklow; Mallory J DiVincenzo; Colin D Angell; William E Carson
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-08-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.